NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
60 trialsNCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05383196 2026-02-11
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT07007559 2026-02-03
ASPEN-09
ALX Oncology Inc.
Phase 1/2 Recruiting
NCT03742102 2026-02-02
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05381038 2025-09-23
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
Phase 1/2 Recruiting
NCT05275777 2025-07-25
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT04331067 2025-04-23
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03568422 2025-03-25
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Active not recruiting
NCT02734290 2025-03-10
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT01084863 2025-01-24
Compare
Celltrion
Phase 1/2 Completed
NCT03616886 2024-12-19
SYNERGY
Jules Bordet Institute
Phase 1/2 Active not recruiting
NCT03356860 2024-11-20
B-IMMUNE
Grand Hôpital de Charleroi
Phase 1/2 Completed
NCT02938442 2024-11-07
Vaccination of Triple Negative Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT06202261 2024-03-12
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03411161 2021-05-25
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
Servier
Phase 1/2 Completed
NCT02041429 2021-04-21
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00470301 2021-02-16
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01495247 2020-12-08
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 1/2 Terminated
NCT00574587 2020-10-14
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Albert Einstein College of Medicine
Phase 1/2 Completed
NCT01697293 2020-09-24
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Prescient Therapeutics, Ltd.
Phase 1/2 Terminated
NCT00003086 2020-07-14
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Terminated
NCT02628132 2020-07-07
Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
King Faisal Specialist Hospital & Research Center
Phase 1/2 Completed
NCT01484080 2020-01-27
Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1/2 Completed
NCT00820170 2019-08-13
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01980277 2019-01-23
TAKTIC
Institut Paoli-Calmettes
Phase 1/2 Terminated
NCT02297230 2018-10-15
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NYU Langone Health
Phase 1/2 Terminated
NCT01031446 2018-08-31
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT00445458 2018-07-26
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT02379585 2018-04-24
STEFNE
Western Regional Medical Center
Phase 1/2 Terminated
NCT01512199 2017-10-18
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Daiichi Sankyo
Phase 1/2 Terminated
NCT00041470 2017-07-17
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
University of Washington
Phase 1/2 Terminated
NCT02396108 2017-02-03
Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT01172223 2016-11-02
LAPADO
Sana-Klinikum Lichtenberg
Phase 1/2 Completed
NCT00691379 2016-09-22
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00887575 2016-09-07
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00951665 2016-06-24
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
Phase 1/2 Completed
NCT01042925 2016-06-03
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
Phase 1/2 Completed
NCT00900627 2016-01-20
THYME
AstraZeneca
Phase 1/2 Completed
NCT00368875 2015-11-05
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01764087 2015-05-18
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1/2 Unknown